MoonLake Immunotherapeutics
MLTX
MLTX
109 hedge funds and large institutions have $3.14B invested in MoonLake Immunotherapeutics in 2024 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 53 increasing their positions, 22 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
2% less funds holding
Funds holding: 111 → 109 (-2)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Holders
109
Holding in Top 10
4
Calls
$6.04M
Puts
$5M
Top Buyers
| 1 | +$65.9M | |
| 2 | +$47M | |
| 3 | +$32.6M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.1M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$17.7M |
Top Sellers
| 1 | -$66.6M | |
| 2 | -$33M | |
| 3 | -$11.3M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.11M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$8.98M |